ADoTope MC003 / Medicovestor - LARVOL DELTA

MC003: ADoTope, a first-in-class dual-payload bi-epitope combination chemoimmunotherapy antibody drug conjugate (ADC) targeting folate receptor alpha in platinum-resistant epithelial ovarian cancer (SITC 2025) - "While the FDA has approved mirvetuximab soravtansine for platinum-resistant ovarian cancer, its clinical performance underscores a persistent unmet need in this highly refractory population. Our data provides preclinical support for the ADoTope platform and justifies advancing MC003 to further development for platinum-resistant ovarian cancer treatment. MC003 is currently in IND-enabling stage of development.Ethics Approval All animal experiments were carried out under the Sanyou Biopharmaceuticals Laboratory Animal Ethics Committee.Abstract 995 Figure 1Request permissions"

IO biomarker • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

MC003: ADoTope, a first-in-class dual-payload bi-epitope combination chemoimmunotherapy antibody drug conjugate (ADC) targeting Folate Receptor Alpha (FRa) in platinum-resistant epithelial ovarian cancer. (AACR-NCI-EORTC 2025) - "While the FDA has approved mirvetuximab soravtansine for platinum-resistant ovarian cancer, its clinical performance underscores a persistent unmet need in this highly refractory population. Our data provides preclinical support for the ADoTope platform and justifies advancing MC003 to further development for platinum-resistant ovarian cancer treatment. MC003 is currently in IND-enabling stage of development."

IO biomarker • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1